Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806312 | 0.90 | S1PR2 (0.35) | KDM4EALDH1A1HTTS1PR2S1PR1 | |
| SCHEMBL6810050 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL6809721 | 0.79 | LTA4H (0.40) | SMN1; SMN2KDM4EALDH1A1L3MBTL1HTT | |
| SCHEMBL6804996 | 0.77 | LTA4H (0.48) | KDM4EL3MBTL1MAPTPPARA | |
| SCHEMBL7013799 | 0.72 | LTA4H (0.39) | KDM4EALDH1A1HTTMAPT | |
| SCHEMBL6702139 | 0.70 | ITGB3 (0.48) | SMN1; SMN2KDM4EALDH1A1MTNR1AMTNR1B | |
| SCHEMBL6803385 | 0.70 | HSD17B2 (0.51) | KDM4EALDH1A1 | |
| SCHEMBL7524219 | 0.68 | ITGB3 (0.52) | L3MBTL1MAPT | |
| SCHEMBL7524212 | 0.68 | ITGB3 (0.52) | L3MBTL1MAPT | |
| SCHEMBL14242912 | 0.66 | FDPS (0.51) | SMN1; SMN2KDM4EALDH1A1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| EP-1313705-A1 | GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6531494-B1 | Gem-substituted αvβ3 antagonists | PHARMACIA CORPORATION | 2003-03-11 | — | — | US | disclosed |
| WO-2002018340-A1 | GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | CACNG5, ITGAV, ITGA5 | SMN1; SMN2 1777/4885KDM4E 2064/4885ALDH1A1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.